Apellis Pharmaceuticals (NASDAQ:APLS) issued its quarterly earnings data on Friday. The company reported ($1.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.23), Fidelity Earnings reports.
NASDAQ:APLS opened at $25.89 on Friday. Apellis Pharmaceuticals has a twelve month low of $16.85 and a twelve month high of $45.04. The company has a debt-to-equity ratio of 0.60, a current ratio of 13.25 and a quick ratio of 13.25. The company’s 50 day moving average is $31.18 and its two-hundred day moving average is $33.44.
In other news, CEO Cedric Francois sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $32.12, for a total value of $160,600.00. Following the sale, the chief executive officer now directly owns 1,098,079 shares of the company’s stock, valued at approximately $35,270,297.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Alec Machiels sold 2,500 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $30.21, for a total transaction of $75,525.00. In the last three months, insiders have sold 13,350 shares of company stock worth $414,741. 9.50% of the stock is owned by insiders.
A number of equities research analysts recently weighed in on APLS shares. UBS Group started coverage on Apellis Pharmaceuticals in a research report on Thursday, May 28th. They set an “add” rating on the stock. Oppenheimer reaffirmed a “buy” rating and set a $62.00 price objective on shares of Apellis Pharmaceuticals in a research report on Friday, June 12th. BidaskClub downgraded Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. Citigroup dropped their price objective on Apellis Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Finally, Roth Capital began coverage on Apellis Pharmaceuticals in a report on Monday, July 20th. They issued a “buy” rating and a $50.00 price target for the company. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $50.92.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Featured Article: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.